Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer

To join this study, you would need to have endometrial cancer that has either come back or spread to other parts of your body. Doctors must have confirmed this cancer using a biopsy. You also need to show that your cancer has grown after your most recent treatment, and doctors must be able to measure your cancer using scans.

Before considering this study, you would need to have already received at least one course of chemotherapy treatment that contained a drug called platinum. The good news is that previous hormone therapy, other targeted treatments, or radiotherapy usually won't stop you from joining. You must be at least 18 years old and in generally good health, meaning you can carry out most of your usual daily activities. Your blood test results, like your liver function and blood cell counts, would also need to be within a healthy range.

There are also specific details your doctor will check regarding your tumour, such as its 'microsatellite instability (MSI)' status, which helps guide treatment decisions. The research team would need to be able to get a sample of your tumour tissue that was taken previously, for further analysis.

If you decide to take part in this study, the first step is a randomisation process, like flipping a coin, to decide which treatment group you'll be in. You'll either receive both cabozantinib and nivolumab, or nivolumab on its own. Cabozantinib is a tablet you take by mouth once a day. Nivolumab is given through a drip into your vein (intravenously) over about 30 minutes, usually on specific days during a treatment cycle.

Throughout the study, you'll have regular hospital visits for check-ups, blood tests, and to receive your treatment. You'll also have scans, like CT scans or MRI scans, to see how your cancer is responding to the treatment. These scans might be done at the start and then periodically during your treatment. The study team will explain the exact schedule of visits and tests to you in detail.

The total duration of your participation would depend on how your body responds to the treatment. You would continue treatment for as long as it is benefiting you and you are tolerating it well. You'll be closely monitored for any side effects and your general health throughout the study.